Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PicTURE: 99mTc-Duramycin biodistribution
NCT05177640Phase 1Completed
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 99mtc-duramycin in solid tumor. Primary endpoints: Biodistribution of [99mTc]Duramycin at 24 hours and Dosimetry evaluation of [99mTc]Duramycin at 24 hours. Started Jun 2021; status: completed.
02
Drugs
99mtc-duramycin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05177640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177640.